JMP Genomics shows the future of biomarker discovery
The Biomarkers Congress is Europe’s largest biomarkers event showcasing case studies in biomarker discovery, and validation strategies and regulation. Its industry delegate list reads like a who’s who in the world of biomarkers, with representation from throughout the globe, for example, AstraZeneca, GSK, Merck, Roche and Takeda. It was fantastic to catch up with JMP customers at the conference over the past couple of days.
Effective use of biomarkers is seen as an increasingly important strategy as pharmaceutical companies look to find new business streams based around personalised medicine.
A common theme at the conferences was the need to work with integrated data types. For example, researchers would like to be able to evaluate proteomic, metabolomics and gene data simultaneously and look for relationships between these different data. In addition, they would also like to develop predictive models that consider all data types as candidate predictors as opposed to evaluating each data set separately.
JMP Genomics and JMP Clinical have tools that address these needs. The cross-correlation feature will look for relationships between all possible combinations of data, and the predictive modeling tools can accommodate categorical and continuous data as candidate predictors.
Doug Robinson, JMP’s in-field life sciences specialist, presented a talk on how to explore and link genomics and clinical data visually. He showed JMP Genomics and shared information about some of the new features coming in the next release, due out in May this year.